Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cantargia AB ( (SE:CANTA) ) has shared an announcement.
Cantargia AB has published preclinical data in Cancer Discovery, demonstrating that targeting IL1RAP with nadunolimab can counteract tumor-driven systemic immunosuppression, potentially enhancing the effectiveness of cancer treatment. The findings, supported by clinical data, suggest that nadunolimab could improve outcomes in cancer therapies by reducing immunosuppressive cells and enhancing anti-tumor immune responses, thus positioning Cantargia as a significant player in advancing cancer immunotherapy.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases, with a platform centered on the protein IL1RAP. Their primary oncology program involves the antibody nadunolimab (CAN04), which is being clinically studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. The company is also developing CAN10 for autoimmune and inflammatory diseases.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
Find detailed analytics on CANTA stock on TipRanks’ Stock Analysis page.